Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsTimothy P. Cripe, Kevin A. Cassady, Pin-Yi Wang, Julia K. Halley
Life of this patent
Estimating the term…
Abstract
The disclosure provides a non-natural herpes simplex virus (“HSV”), compositions comprising, or alternatively consisting essentially of, or yet further consisting of the HSV, and methods of producing the HSV, or infecting a cell with the HSV. Also provided herein are methods of treating cancer or inhibiting the growth or metastasis of cancer cell in a subject in need thereof.
Claims51
A non-natural herpes simplex virus (“HSV”), wherein the virus comprises one or more mutation(s) in a virulence gene that is from the group of:
- (a) a glycoprotein E (“gE”)-encoding gene,
- (b) an Infected Cell Protein 0 (“ICP0”)-encoding gene,
- (c) a DNA packaging terminase subunit 1-encoding gene,
- (d) an ICP8-encoding gene, or
- (e) an ICP34.5-encoding gene.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.